Download PDF
CC BY 4.0 · Eur J Dent 2023; 17(01): 024-038
DOI: 10.1055/s-0042-1751003
Review Article

Onset of Mucormycosis in Patients with COVID-19: A Systematic Review on Patients' Characteristics

Shohreh Ghasemi 
1   Department of Oral and Maxillofacial Surgery, The Dental College of Georgia at Augusta University, Augusta, GA, USA
2   Department of Craniofacial Reconstruction and Trauma Queen Marry, University of London, London, UK
,
Mahmood Dashti 
3   Department of Orthodontics, Georgia School of Orthodontics, Atlanta, Georgia, USA
,
Amir Fahimipour 
4   Department of Oral Surgery, Medicine and Diagnostics, School of Dentistry, Faculty of Medicine and Health, Westmead Centre for Oral Health, The University of Sydney, Sydney, Australia
,
Ghazaleh Daryakenari 
5   Department of Oral and Maxillofacial Surgery, Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
,
Fatemeh Mirzaei 
6   Student Research Committee, Golestan University of Medical Sciences, Gorgan, Iran
,
Fatemeh Akbari 
7   Department of Dentistry, Mazandaran University of Medical Science, Mazandaran, Iran
,
Zohaib Khurshid
8   Department of Prosthodontics and Dental Implantology, College of Dentistry, King Faisal University, Al-Ahsa, Kingdom of Saudi Arabia
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Mucormycosis has a significant impact on patients' standard of living and, therefore, a high clinical suspicion, prediagnosis, and rapid treatment are critical in easing patients' suffering and fast recovery. Our focus is to conduct an organized review based on various variables on the patients' characteristics having mucormycosis in severe novel coronavirus disease 2019 (COVID-19). We examined Embase, PubMed-Medline, LitCovid, Web of Science, Scopus, and the reference lists of included case reports up to September 20, 2021, using the Medical Subject Heading (MeSH) phrases and other keywords related to this topic. Subsequently, we investigated associated comorbidities, patient characteristics, position of mucormycosis, steroids use, body involvements, and outcomes. Overall, 77 studies were conducted and among these, 72 studies mentioned that the patients' age to be 48.13±14.33 (mean±standard deviation [SD]) years. Diabetes mellitus (DM) was reported in 77.9% (n=60) of cases. Studies showed that central nervous system (CNS) and bone involvement were reported in 62.3 (n=48) and 53.2% (n=41), respectively. More fatalities were observed in patients with mucormycosis with the active form of COVID-19. Also, men infected with mucormycosis significantly affected by COVID-19. In the end, mortality was higher in males with mucormycosis. As a result, a solid investigation into the root cause of mucormycosis, especially in COVID-19, should be included in the study plan. If the patient is COVID-19-positive and immunosuppressed, this opportunistic pathogen diagnostic test should not be overlooked.

Keywords

novel coronavirus disease 2019 - COVID-19-associated candidiasis - mucormycosis - corticosteroid treatment - fungal co infections

Consent for Publication

All authors, give their consent for the publication of identifiable details which can include photograph(s) and/or videos and/or case history and/or details within the text (“Material”) to be published in the above Journal and Article.


Availability of Data and Materials

All data generated or analyzed during this study are included in this published article (and its supplementary information files).


Authors' Contributions

S.G. and M.D. conceptualized; F.A. and F.M. searched the literature and created the first draft; M.D. created the table and analyzed the data; A.F and G.D.K. prepared the first draft; And S. G., M.D., and Z.K. reviewed the first draft and edited the final draft. All authors mutually agree to submit for publication.




Publication History

Article published online:
01 September 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
    CrossrefPubMedGoogle Scholar
  • 2 Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323 (13) 1239-1242
    CrossrefPubMedGoogle Scholar
  • 3 Elitzur S, Arad-Cohen N, Barg A. et al. Mucormycosis in children with haematological malignancies is a salvageable disease: a report from the Israeli Study Group of Childhood Leukemia. Br J Haematol 2020; 189 (02) 339-350
    CrossrefPubMedGoogle Scholar
  • 4 Garg D, Muthu V, Sehgal IS. et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021; 186 (02) 289-298
    CrossrefPubMedGoogle Scholar
  • 5 Zhu N, Zhang D, Wang W. et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382 (08) 727-733
    CrossrefPubMedGoogle Scholar
  • 6 Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect 2020; 26 (10) 1395-1399
    CrossrefPubMedGoogle Scholar
  • 7 Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med 2021; 42 (264) 264.e5-264.e8
    CrossrefPubMedGoogle Scholar
  • 8 Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535
    Google Scholar
  • 9 Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China. Mycopathologia 2020; 185 (04) 599-606
    CrossrefPubMedGoogle Scholar
  • 10 Chegini Z, Didehdar M, Khoshbayan A, Rajaeih S, Salehi M, Shariati A. Epidemiology, clinical features, diagnosis and treatment of cerebral mucormycosis in diabetic patients: a systematic review of case reports and case series. Mycoses 2020; 63 (12) 1264-1282
    CrossrefPubMedGoogle Scholar
  • 11 Ahmadikia K, Hashemi SJ, Khodavaisy S. et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses 2021; 64 (08) 798-808
    Google Scholar
  • 12 Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 2021; 135 (05) 442-447
    CrossrefPubMedGoogle Scholar
  • 13 Einollahi B, Lessan-Pezeshki M, Aslani J. et al. Two decades of experience in mucormycosis after kidney transplantation. Ann Transplant 2011; 16 (03) 44-48
    CrossrefPubMedGoogle Scholar
  • 14 Chaulk AL, Do TH, Supsupin EP, Bhattacharjee MB, Richani K, Adesina O. A unique radiologic case of optic nerve infarction in a patient with mucormycosis. J Neuroophthalmol 2021; 41 (03) e354-e356
    CrossrefPubMedGoogle Scholar
  • 15 Dallalzadeh LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. Orbit 2021; 1-4
    PubMedGoogle Scholar
  • 16 Iyer M, Tiwari S, Renu K. et al. Environmental survival of SARS-CoV-2 - A solid waste perspective. Environ Res 2021; 197: 111015
    CrossrefPubMedGoogle Scholar
  • 17 Jayaramayya K, Mahalaxmi I, Subramaniam MD. et al. Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment. BMB Rep 2020; 53 (08) 400-412
    CrossrefPubMedGoogle Scholar
  • 18 Kumar P. Centre Asks States to Notify “Black Fungus” under Epidemic Diseases Act. NDTV. Accessed May 20, 2022 at: https://www.ndtv.com/video/news/the-news/centre-asks-states-to-notify-black-fungus-under-epidemic-diseases-act-586925
    Google Scholar
  • 19 Mekonnen ZK, Ashraf DC, Jankowski T. et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthal Plast Reconstr Surg 2021; 37 (02) e40-e80
    CrossrefPubMedGoogle Scholar
  • 20 Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases 2021; 12 (03) 85-89
    CrossrefPubMedGoogle Scholar
  • 21 Shafiekhani M, Shahabinezhad F, Niknam T. et al. Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand?. Virol J 2021; 18 (01) 228
    CrossrefPubMedGoogle Scholar
  • 22 Mehrabi Z, Salimi M, Niknam K. et al. Sinoorbital mucormycosis associated with corticosteroid therapy in COVID-19 infection. Case Rep Ophthalmol Med 2021; 2021: 9745701
    PubMedGoogle Scholar
  • 23 Baban B, Stevens MR, Ghasemi S, Boojar FMA, Dashti M. New manifestation of Covid-19 in oral region, a potential faster diagnosis approach, a mini review. J Dent Oral Epidemiol 2021;1(01):
    Google Scholar
  • 24 Ghasemi S, Dashti M. New unknown SARS-CoV-2 virus variants and hidden pandemics within them in developing countries. Res Square 2021; DOI: 10.21203/rs.3.rs-898454/v1.
    CrossrefGoogle Scholar
  • 25 Alfishawy M, Elbendary A, Younes A. et al. Diabetes mellitus and coronavirus disease (COVID-19) associated mucormycosis (CAM): a wake-up call from Egypt. Diabetes Metab Syndr 2021; 15 (05) 102195
    CrossrefPubMedGoogle Scholar
  • 26 Arana C, Cuevas Ramírez RE, Xipell M. et al. Mucormycosis associated with COVID-19 in two kidney transplant patients. Transpl Infect Dis 2021; 23 (04) e13652
    CrossrefPubMedGoogle Scholar
  • 27 Arjun R, Felix V, Niyas VKM. et al. COVID-19 associated rhino-orbital mucormycosis: a single centre experience of ten cases. QJM 2021; 114 (11) 831-834
    CrossrefPubMedGoogle Scholar
  • 28 Ashour MM, Abdelaziz TT, Ashour DM, Askoura A, Saleh MI, Mahmoud MS. Imaging spectrum of acute invasive fungal rhino-orbital-cerebral sinusitis in COVID-19 patients: a case series and a review of literature. J Neuroradiol 2021; 48 (05) 319-324
    CrossrefPubMedGoogle Scholar
  • 29 Awal SS, Biswas SS, Awal SK. Rhino-orbital mucormycosis in COVID-19 patients—a new threat?. Egypt J Radiol Nucl Med 2021; 52 (01) 152
    CrossrefGoogle Scholar
  • 30 Baskar HC, Chandran A, Reddy CS, Singh S. Rhino-orbital mucormycosis in a COVID-19 patient. BMJ Case Rep 2021; 14 (06) e244232
    CrossrefPubMedGoogle Scholar
  • 31 Bayram N, Ozsaygılı C, Sav H. et al. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. Jpn J Ophthalmol 2021; 65 (04) 515-525
    CrossrefPubMedGoogle Scholar
  • 32 Bonates P, João GAP, Cruz KS. et al. Fatal rhino-orbito-cerebral mucormycosis infection associated with diabetic ketoacidosis post-COVID-19. Rev Soc Bras Med Trop 2021; 54: e03582021
    CrossrefPubMedGoogle Scholar
  • 33 Buil JB, van Zanten ARH, Bentvelsen RG. et al. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Euro Surveill 2021; 26 (23) 2100510
    PubMedGoogle Scholar
  • 34 Chauhan K, Soni D, Sarkar D. et al. Mucormycosis after COVID-19 in a patient with diabetes. Lancet 2021; 398 (10301): e10
    CrossrefPubMedGoogle Scholar
  • 35 Dave TV, Gopinathan Nair A, Hegde R. et al. Clinical presentations, management and outcomes of rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19: a multi-centric study. Ophthalmic Plast Reconstr Surg 2021; 37 (05) 488-495
    CrossrefPubMedGoogle Scholar
  • 36 Desai EJ, Pandya A, Upadhya I, Patel T, Banerjee S, Jain V. Epidemiology, clinical features and management of rhino orbital mucormycosis in post COVID 19 patients. Indian J Otolaryngol Head Neck Surg 2022; 74 (01) 103-107
    CrossrefPubMedGoogle Scholar
  • 37 Desai SM, Gujarathi-Saraf A, Agarwal EA. Imaging findings using a combined MRI/CT protocol to identify the “entire iceberg” in post-COVID-19 mucormycosis presenting clinically as only “the tip”. Clin Radiol 2021; 76 (10) 784.e27-784.e33
    CrossrefPubMedGoogle Scholar
  • 38 Eswaran S, Balan SK, Saravanam PK. Acute fulminant mucormycosis triggered by Covid 19 infection in a young patient. Indian J Otolaryngol Head Neck Surg 2021; (e-pub ahead of print). DOI: 10.1007/s12070-021-02689-4.
    CrossrefPubMedGoogle Scholar
  • 39 Avatef Fazeli M, Rezaei L, Javadirad E. et al. Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: an observational study. Mycoses 2021; 64 (11) 1366-1377
    CrossrefPubMedGoogle Scholar
  • 40 Fouad YA, Abdelaziz TT, Askoura A. et al. Spike in rhino-orbital-cerebral mucormycosis cases presenting to a tertiary care center during the COVID-19 pandemic. Front Med (Lausanne) 2021; 8: 645270
    CrossrefPubMedGoogle Scholar
  • 41 Garg R, Bharangar S, Gupta S, Bhardwaj S. Post Covid-19 infection presenting as rhino-orbital mycosis. Indian J Otolaryngol Head Neck Surg 2021; (e-pub ahead of print). DOI: 10.1007/s12070-021-02722-6.
    CrossrefPubMedGoogle Scholar
  • 42 Gupta DP, Gupta S, Shah CK, Sreevidya SR. Clinical study of surge of mucormycosis in covid-19 pandemic: a tertiary care center study. Indian J Otolaryngol Head Neck Surg 2021; (e-pub ahead of print). DOI: 10.1007/s12070-021-02784-6.
    CrossrefPubMedGoogle Scholar
  • 43 Gupta KK, Singh A, Kalia A, Kandhola R. Anaesthetic considerations for post-COVID-19 mucormycosis surgery- a case report and review of literature. Indian J Anaesth 2021; 65 (07) 545-547
    CrossrefPubMedGoogle Scholar
  • 44 Gupta NK, Kapre M, Gupta H. et al. Risk Based Decision Algorithms for management of COVID-19 associated rhino-orbital mucormycosis. Indian J Otolaryngol Head Neck Surg 2022; 74 (Suppl. 02) 3447-3454 DOI: 10.1007/s12070-021-02692-9.
    CrossrefPubMedGoogle Scholar
  • 45 Kumar Gupta S, Jyotsana P, Singh A, Phuyal D, Allam P. Rhinocerebral mucormycosis in a covid-19 patient from nepal: a case report. JNMA J Nepal Med Assoc 2021; 59 (239) 703-705
    PubMedGoogle Scholar
  • 46 Hooli SA, Gadre VN, Bage S, Gilvarkar MD. The aftermath of COVID-19 pandemic: rhino-orbital mucormycosis. Indian J Anaesth 2021; 65 (07) 548-553
    CrossrefPubMedGoogle Scholar
  • 47 Jy Ong J, Cy Chan A, Sharma AK, Sharma S, Sharma VK. The mucormycosis epidemic within COVID-19 pandemic- lessons from India. Brain Behav Immun 2021; 97: 4-5
    CrossrefPubMedGoogle Scholar
  • 48 Karimi-Galougahi M, Arastou S, Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol 2021; 11 (06) 1029-1030
    CrossrefPubMedGoogle Scholar
  • 49 Kaur H, Kanaujia R, Rudramurthy SM. Rhizopus homothallicus: An emerging pathogen in era of COVID-19 associated mucormycosis. Indian J Med Microbiol 2021; 39 (04) 473-474
    CrossrefPubMedGoogle Scholar
  • 50 Krishna V, Morjaria J, Jalandari R, Omar F, Kaul S. Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. IDCases 2021; 25: e01172
    CrossrefPubMedGoogle Scholar
  • 51 Kumari A, Rao NP, Patnaik U. et al. Management outcomes of mucormycosis in COVID-19 patients: a preliminary report from a tertiary care hospital. Med J Armed Forces India 2021; 77: S289-S295
    CrossrefPubMedGoogle Scholar
  • 52 Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: a case report. Int J Surg Case Rep 2021; 82: 105957
    CrossrefPubMedGoogle Scholar
  • 53 Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020; 12 (09) e10726
    CrossrefPubMedGoogle Scholar
  • 54 Meshram HS, Kute VB, Chauhan S, Desai S. Mucormycosis in post-COVID-19 renal transplant patients: a lethal complication in follow-up. Transpl Infect Dis 2021; 23 (04) e13663
    CrossrefPubMedGoogle Scholar
  • 55 Mishra Y, Prashar M, Sharma D. , Akash, Kumar VP, Tilak TVSVGK. Diabetes, COVID 19 and mucormycosis: Clinical spectrum and outcome in a tertiary care medical center in Western India. Diabetes Metab Syndr 2021; 15 (04) 102196
    CrossrefPubMedGoogle Scholar
  • 56 Mitra S, Janweja M, Sengupta A. Post-COVID-19 rhino-orbito-cerebral mucormycosis: a new addition to challenges in pandemic control. Eur Arch Otorhinolaryngol 2022; 279 (05) 2417-2422
    CrossrefPubMedGoogle Scholar
  • 57 Moorthy A, Gaikwad R, Krishna S. et al. SARS-CoV-2, uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. J Maxillofac Oral Surg 2021; 20 (03) 418-425
    CrossrefPubMedGoogle Scholar
  • 58 Nair AG, Adulkar NG, D'Cunha L. et al. Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients. Orbit 2021; 40 (06) 499-504
    CrossrefPubMedGoogle Scholar
  • 59 Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19 associated mucormycosis: a life-threatening complication in patients admitted with severe to critical COVID-19 from Pakistan. Clin Microbiol Infect 2021; 27 (11) 1704-1707
    CrossrefPubMedGoogle Scholar
  • 60 Nehara HR, Puri I, Singhal V, Ih S, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India. Indian J Med Microbiol 2021; 39 (03) 380-383
    CrossrefPubMedGoogle Scholar
  • 61 Ostovan VR, Rezapanah S, Behzadi Z. et al. Coronavirus disease (COVID-19) complicated by rhino-orbital-cerebral mucormycosis presenting with neurovascular thrombosis: a case report and review of literature. J Neurovirol 2021; 27 (04) 644-649
    CrossrefPubMedGoogle Scholar
  • 62 Palou EY, Ramos MA, Cherenfant E. et al. Covid-19 associated rhino-orbital mucormycosis complicated by gangrenous and bone necrosis—a case report from honduras. Vaccines (Basel) 2021; 9 (08) 826
    CrossrefPubMedGoogle Scholar
  • 63 Pasero D, Sanna S, Liperi C. et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection 2021; 49 (05) 1055-1060
    CrossrefPubMedGoogle Scholar
  • 64 Patel A, Agarwal R, Rudramurthy SM. et al; MucoCovi Network3. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis 2021; 27 (09) 2349-2359
    CrossrefPubMedGoogle Scholar
  • 65 Pathak K, Karadwal A, Nayak P, Nayak S. Mucormycosis in post covid patient-a case report. Indian Journal of Forensic Medicine and Toxicology. 2021; 15 (03) 240-244
    Google Scholar
  • 66 Ramaswami A, Sahu AK, Kumar A. et al. COVID-19-associated mucormycosis presenting to the emergency department-an observational study of 70 patients. QJM 2021; 114 (07) 464-470
    CrossrefPubMedGoogle Scholar
  • 67 Rao R, Shetty AP, Nagesh CP. Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: clinico-radiological features. Indian J Ophthalmol 2021; 69 (06) 1627-1630
    CrossrefPubMedGoogle Scholar
  • 68 Revannavar SM. , P S S, Samaga L, v K V. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?. BMJ Case Rep 2021; 14 (04) e241663
    Google Scholar
  • 69 Roopa R, Thanthoni M, Warrier AS. COVID-19 coinfection with mucormycosis in a diabetic patient. Cureus 2021; 13 (06) e15820
    PubMedGoogle Scholar
  • 70 Roushdy T, Hamid E. A case series of post COVID-19 mucormycosis-a neurological prospective. Egypt J Neurol Psychiat Neurosurg 2021; 57 (01) 100
    CrossrefPubMedGoogle Scholar
  • 71 Sai Krishna D, Raj H, Kurup P, Juneja M. Maxillofacial infections in Covid-19 era-actuality or the unforeseen: 2 case reports. Indian J Otolaryngol Head Neck Surg 2022; 74 (Suppl. 02) 2959-2962 DOI: 10.1007/s12070-021-02618-5.
    CrossrefPubMedGoogle Scholar
  • 72 Saidha PK, Kapoor S, Das P. et al. Mucormycosis of paranasal sinuses of odontogenic origin post COVID19 infection: a case series. Indian J Otolaryngol Head Neck Surg 2022; 74 (Suppl. 02) 3437-3441 DOI: 10.1007/s12070-021-02638-1.
    CrossrefPubMedGoogle Scholar
  • 73 Saldanha M, Reddy R, Vincent MJ. Title of the article: paranasal mucormycosis in COVID-19 patient. Indian J Otolaryngol Head Neck Surg 2022; 74 (Suppl. 02) 3407-3410 DOI: 10.1007/s12070-021-02574-0.
    CrossrefPubMedGoogle Scholar
  • 74 Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol 2021; 69 (04) 1002-1004
    Google Scholar
  • 75 Selarka L, Sharma AK, Rathod G, Saini D, Patel S, Sharma VK. Mucormycosis- a dreaded complication of COVID-19. QJM 2021; 114 (09) 670-671
    CrossrefPubMedGoogle Scholar
  • 76 Selarka L, Sharma S, Saini D. et al. Mucormycosis and COVID-19: an epidemic within a pandemic in India. Mycoses 2021; 64 (10) 1253-1260
    Google Scholar
  • 77 Sen M, Honavar SG, Bansal R. et al; members of the Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) Study Group. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - collaborative OPAI-IJO study on mucormycosis in COVID-19 (COSMIC), report 1. Indian J Ophthalmol 2021; 69 (07) 1670-1692
    CrossrefPubMedGoogle Scholar
  • 78 Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol 2021; 69 (02) 244-252
    CrossrefPubMedGoogle Scholar
  • 79 Sethi HS, Sen KK, Mohanty SS, Panda S, Krishna KR, Mali C. COVID-19-associated rhino-orbital mucormycosis (CAROM)—a case report. Egypt J Radiol Nucl Med 2021; 52 (01) 165 DOI: 10.1186/s43055-021-00547-5.
    CrossrefGoogle Scholar
  • 80 Shakir M, Maan MHA, Waheed S. Mucormycosis in a patient with COVID-19 with uncontrolled diabetes. BMJ Case Rep 2021; 14 (07) e245343
    CrossrefPubMedGoogle Scholar
  • 81 Singh RP, Gupta N, Kaur T, Gupta A. Rare case of gastrointestinal mucormycosis with colonic perforation in an immunocompetent patient with COVID-19. BMJ Case Rep 2021; 14 (07) e244096
    CrossrefPubMedGoogle Scholar
  • 82 Singh Y, Ganesh V, Kumar S. et al. Coronavirus disease-associated mucormycosis from a tertiary care hospital in India: a case series. Cureus 2021; 13 (07) e16152
    PubMedGoogle Scholar
  • 83 Tabarsi P, Khalili N, Pourabdollah M. et al. Case report: COVID-19-associated rhinosinusitis mucormycosis caused by Rhizopus arrhizus: a rare but potentially fatal infection occurring after treatment with corticosteroids. Am J Trop Med Hyg 2021; 105 (02) 449-453
    CrossrefPubMedGoogle Scholar
  • 84 Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. Eur J Ophthalmol 2022; 32 (04) NP11-NP16 DOI: 10.1177/11206721211009450.
    CrossrefPubMedGoogle Scholar
  • 85 Venugopal A, Marya A. Palatal mucormycosis in a patient with SARS-CoV-2 infection. CMAJ 2021; 193 (32) E1254
    CrossrefPubMedGoogle Scholar
  • 86 Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus 2021; 13 (02) e13163
    CrossrefPubMedGoogle Scholar
  • 87 Cordero-Hernández EL, Martínez-Murillo C, Barranco-Lampón G, Arias-Castro I, Santoyo-Sánchez A, Ramos-Peñafiel CO. Mucormycosis, COVID-19 and acute lymphoid leukemia: case report. Arch Intern Med Res 2022; 5 (02) 192-198 DOI: 10.26502/aimr.0101.
    CrossrefGoogle Scholar
  • 88 Mohammadi F, Badri M, Safari S, Hemmat N. A case report of rhino-facial mucormycosis in a non-diabetic patient with COVID-19: a systematic review of literature and current update. BMC Infect Dis 2021; 21 (01) 906
    CrossrefPubMedGoogle Scholar
  • 89 Barman Roy D, Gupta V, Biswas A, Verma M. Early surgical intervention followed by antifungals in rhino-orbital mucormycosis in patients with COVID-19 favors clinical outcome: a case series. Cureus 2021; 13 (08) e17178
    PubMedGoogle Scholar
  • 90 Budhiraja S, Aggarwal M, Mahajan M. et al. Profile of mucormycosis cases from a network of hospitals in North India amidst COVID-19 pandemic. Medrxiv 2021; DOI: 10.1101/2021.08.25.21262404.
    CrossrefGoogle Scholar
  • 91 Pandey S, Wani AA. Intracranial mucormycosis—a minacious foe. Indian J Neurosurg 2021; 10 (02) 92-94
    Article in Thieme ConnectGoogle Scholar
  • 92 Farid HA, Hashim AR, Hasrat NH. Rhinocerebral mucormycosis as a COVID-19-related complication: a case report from Basra city, Southern Iraq. Journal of Global Scientific Research 2021; 6: 1369-1374
    Google Scholar
  • 93 Singh Rathore C, Ansari S, Bajpai T. A case of COVID-19 triggered rhino-orbital pulmonary mucormycosis in Central India. Biomed Res J 2021; 8: 25-28 DOI: 10.4103/bmrj.bmrj_8_21.
    CrossrefGoogle Scholar
  • 94 Rostamihosseinkhani M, Hooshmandi E, Janipour M, Fadakar N. True mycotic aneurysms: a report of three patients with internal carotid artery aneurysm and mucormycosis, and literature review. Res Square 2021; DOI: 10.21203/rs.3.rs-853134/v1.
    CrossrefGoogle Scholar
  • 95 Joshi AR, Muthe MM, Patankar SH, Athawale A, Achhapalia Y. CT and MRI findings of invasive mucormycosis in the setting of COVID-19: experience from a single center in India. AJR Am J Roentgenol 2021; 217 (06) 1431-1432
    CrossrefPubMedGoogle Scholar